SMMT

Summit Therapeutics Inc. NASDAQ Listed Mar 5, 2015

Healthcare ·Biotechnology ·US · summittxinc.com

$17.85

After hrs $17.80 -0.28%

Mkt Cap $13.8B

52w Low $13.83 23.4% of range 52w High $30.98

50d MA $18.41 200d MA $19.62

P/E (TTM) -11.2x

EV/EBITDA -16.1x

P/B 18.3x

Debt/Equity 0.0x

ROE -163.9%

P/FCF -40.4x

RSI (14) —

ATR (14) —

Beta -1.37

50d MA $18.41

200d MA $19.62

Avg Volume 2.9M

About

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials fo…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 30, 2026	AMC	-0.27	-0.24	+10.8%	21.46	-25.3%	-24.9%	-20.9%	-18.3%	—	—	—
Feb 23, 2026	AMC	-0.10	-0.29	-182.6%	16.09	-1.9%	+0.2%	-2.5%	-1.8%	+3.1%	+0.6%	—
Oct 20, 2025	AMC	-0.18	-0.31	-76.3%	20.04	-0.2%	-6.5%	-4.4%	-6.4%	-3.8%	-2.9%	—
Aug 11, 2025	AMC	-0.09	-0.76	-736.9%	28.25	-4.2%	-9.1%	-4.9%	-6.4%	-5.5%	-6.9%	—
May 1, 2025	AMC	-0.09	-0.09	+3.2%	24.67	+5.1%	+13.1%	+13.6%	-1.9%	-1.5%	-0.1%	—
Feb 24, 2025	AMC	-0.08	-0.08	+2.2%	18.84	+1.9%	-3.9%	-2.9%	-1.9%	+9.8%	+1.5%	—
Oct 30, 2024	AMC	-0.07	-0.08	-14.3%	18.65	+0.5%	-0.3%	+1.8%	+7.0%	+9.3%	+12.0%	—
Aug 6, 2024	AMC	-0.06	-0.05	+16.7%	9.54	-0.4%	-1.5%	+7.3%	+13.0%	+15.1%	+17.9%	—
May 1, 2024	AMC	-0.06	-0.06	+0.0%	4.70	-0.4%	-13.6%	-6.6%	-4.9%	+13.0%	+5.5%	—
Feb 20, 2024	AMC	—	-0.04	—	3.74	+0.0%	+9.9%	+15.0%	+24.1%	+19.3%	+17.6%	—
Nov 7, 2023	AMC	—	-0.03	—	1.92	-0.3%	-4.7%	-8.4%	-0.5%	-3.9%	+2.9%	—
Aug 9, 2023	AMC	—	-0.02	—	1.94	+0.5%	-8.2%	-11.3%	+2.1%	-1.0%	-8.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Piper Sandler	Maintains	Neutral → Neutral	—	$21.46	$16.02	-25.3%	-24.9%	—	—	—	—
Apr 8	Stifel	Maintains	Buy → Buy	—	$19.22	$19.99	+4.0%	-2.1%	+0.5%	+2.3%	+4.2%	+8.5%
Mar 16	Jefferies	Downgrade	Buy → Hold	—	$16.12	$16.07	-0.3%	+0.4%	-1.7%	-3.2%	-2.5%	-3.8%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.09	$15.78	-1.9%	+0.2%	-2.5%	-1.8%	+3.1%	+0.6%
Feb 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.48	$14.21	-1.9%	-2.9%	+0.8%	-0.4%	-4.4%	+3.5%
Jan 30	Citizens	Maintains	Market Outperform → Market Outperform	—	$15.40	$15.20	-1.3%	-6.0%	-8.7%	-5.3%	-6.4%	-10.1%
Dec 17	Barclays	Upgrade	Underweight → Equal Weight	—	$17.23	$17.65	+2.4%	-1.3%	-1.1%	+3.4%	+5.3%	+5.2%
Oct 22	Guggenheim	Maintains	Buy → Buy	—	$18.74	$19.58	+4.5%	+2.2%	+0.1%	+2.9%	+3.8%	+2.6%
Oct 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.04	$19.99	-0.2%	-6.5%	-4.4%	-6.4%	-3.8%	-2.9%
Oct 21	Barclays	Maintains	Underweight → Underweight	—	$20.04	$19.99	-0.2%	-6.5%	-4.4%	-6.4%	-3.8%	-2.9%
Oct 20	Citigroup	Maintains	Buy → Buy	—	$20.99	$18.85	-10.2%	-4.5%	-10.7%	-8.7%	-10.7%	-8.1%
Oct 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$20.99	$18.85	-10.2%	-4.5%	-10.7%	-8.7%	-10.7%	-8.1%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.94	$18.99	+0.3%	-4.3%	-4.5%	+1.5%	-0.3%	+0.8%
Sep 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$25.98	$21.53	-17.1%	-25.1%	-27.5%	-32.2%	-28.4%	-27.1%
Sep 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.98	$21.53	-17.1%	-25.1%	-27.5%	-32.2%	-28.4%	-27.1%
Sep 3	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$23.84	$23.82	-0.1%	-1.3%	-0.2%	+9.0%	-18.4%	-21.0%
Sep 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.70	$23.13	-2.4%	+0.6%	-0.8%	+0.4%	+9.6%	-17.9%
Aug 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.98	$26.23	-2.8%	-8.0%	-9.5%	-12.2%	-11.6%	-12.8%
Aug 19	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$26.29	$25.63	-2.5%	-3.6%	-1.6%	-1.1%	-0.3%	-0.1%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.45	$26.49	+0.2%	+0.9%	-0.6%	-4.2%	-2.2%	-1.7%
Aug 12	Evercore ISI	Maintains	Outperform → Outperform	—	$28.25	$27.06	-4.2%	-9.1%	-4.9%	-6.4%	-5.5%	-6.9%
Jul 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.28	$21.28	+0.0%	-0.4%	+6.3%	+15.4%	+6.2%	+8.0%
Jun 2	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$18.22	$18.81	+3.2%	-2.7%	+13.2%	+7.4%	+8.3%	+13.0%
May 2	Goldman Sachs	Maintains	Buy → Buy	—	$24.67	$25.93	+5.1%	+13.1%	+13.6%	-1.9%	-1.5%	-0.1%
Apr 28	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$23.47	$24.38	+3.9%	+2.7%	+0.6%	+2.8%	+5.1%	+18.9%
Apr 25	Jefferies	Maintains	Buy → Buy	—	$36.70	$34.48	-6.0%	-36.0%	-34.3%	-35.6%	-34.3%	-32.8%
Apr 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.35	$29.95	+9.5%	+21.5%	+34.2%	-14.2%	-11.8%	-13.6%
Mar 26	Citigroup	Upgrade	Neutral → Buy	—	$20.24	$21.45	+6.0%	-1.7%	+1.8%	+0.4%	-4.7%	-7.1%
Feb 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.84	$19.20	+1.9%	-3.9%	-2.9%	-1.9%	+9.8%	+1.5%
Feb 25	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$18.84	$19.20	+1.9%	-3.9%	-2.9%	-1.9%	+9.8%	+1.5%
Jan 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.03	$19.25	+1.2%	+16.1%	+23.6%	+29.5%	+24.9%	+23.6%
Nov 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.31	$18.36	+0.3%	+3.7%	+9.2%	+1.7%	+0.6%	+3.8%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.65	$18.75	+0.5%	-0.3%	+1.8%	+7.0%	+9.3%	+12.0%
Aug 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.31	$12.40	+0.7%	+8.4%	+9.8%	+6.3%	+7.6%	+9.4%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.12	$11.45	+3.0%	+6.7%	+4.3%	+10.2%	+10.7%	+20.0%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.25	$11.57	+2.8%	-1.2%	+5.5%	+3.1%	+8.9%	+9.4%
Jun 3	Stifel	Maintains	Buy → Buy	—	$8.69	$9.84	+13.2%	+1.7%	-15.9%	-7.5%	-6.4%	-11.2%
May 31	Citigroup	Maintains	Buy → Buy	—	$10.92	$9.07	-16.9%	-20.4%	-19.0%	-33.1%	-26.4%	-25.5%
Nov 25	Oppenheimer	Maintains	Outperform → Outperform	—	$4.21	$4.20	-0.2%	+1.7%	+3.1%	+6.9%	+13.8%	+11.9%
Nov 25	SunTrust Robinson Humphrey	Downgrade	Buy → Hold	—	$4.21	$4.20	-0.2%	+1.7%	+3.1%	+6.9%	+13.8%	+11.9%
Nov 25	Janney Capital	Downgrade	Buy → Neutral	—	$4.21	$4.20	-0.2%	+1.7%	+3.1%	+6.9%	+13.8%	+11.9%
Nov 25	H.C. Wainwright	Maintains	Buy → Buy	—	$4.21	$4.20	-0.2%	+1.7%	+3.1%	+6.9%	+13.8%	+11.9%
Nov 18	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$4.58	$4.32	-5.7%	-1.3%	-1.1%	-3.9%	-3.9%	-8.1%
Mar 19	H.C. Wainwright	Maintains	Buy → Buy	—	$2.75	$2.71	-1.5%	-2.9%	-14.9%	-25.1%	-22.9%	-13.8%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.75	$2.71	-1.5%	-2.9%	-14.9%	-25.1%	-22.9%	-13.8%
Jun 28	Janney Capital	Downgrade	Buy → Neutral	—	$2.55	$2.52	-1.2%	-6.7%	-3.9%	-2.7%	+2.0%	-3.1%
Jun 28	Janney Montgomery Scott	Downgrade	Buy → Neutral	—	$2.55	$2.52	-1.2%	-6.7%	-3.9%	-2.7%	+2.0%	-3.1%
Jun 27	SunTrust Robinson Humphrey	Downgrade	Buy → Hold	—	$12.65	$2.90	-77.1%	-79.8%	-81.2%	-80.6%	-80.4%	-79.4%
May 2	Janney Capital	Maintains	Buy → Buy	—	$13.42	$13.50	+0.6%	+2.5%	+2.5%	+2.4%	+2.6%	+2.5%
Feb 13	BTIG Research	Maintains	Buy → Buy	—	$10.80	$11.06	+2.4%	+6.7%	+11.6%	+12.8%	+8.1%	+5.7%

Recent Filings

8-K · 7.01 ! Medium

Summit Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure

Summit Therapeutics will present fourth-quarter and full-year 2025 financial results on February 23, 2026, providing investors with operational updates via earnings call slides.

Feb 23

Data updated apr 27, 2026 1:56am · Source: massive.com